PSNL
Personalis, Inc.
NASDAQ · USHealthcareMedical - Diagnostics & Research
$13.34-13.32%
Price as of Jul 20, 2026
PSNL growth
Personalis, Inc. growth
Reported trailing growth, forward expectations and three-year compound growth rates.
Trailing growth
Year over year
- Revenue
- -24.7%
- EBITDA
- -16.7%
- EBIT
- -52.8%
- EPS
- +20.9%
- Free cash flow
- -81.2%
- Operating cash flow
- -86.1%
Forward estimates
- Revenue
- +47.6%
- EBITDA
- +43.9%
- EPS
- +0.0%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -1.0%
- EBIT
- -29.0%
- Net income
- +0.0%
- EPS
- +33.6%
- Free cash flow
- -69.9%
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.